MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

To determine whether a punctuated six-month course of ARV therapy during treatment of active TB will delay HIV disease progression, as measured by time until CD4+ count falls below 250 cells/µL, the ...

A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

This is a preview. Log in through your library . Abstract Background. The extended use of antiretroviral drugs among human immunodeficiency virus (HIV)-seropositive individuals underscores the need ...

Globally, in 2020, 38 million people were living with HIV with an additional 1.5 million newly infected. During this period, 73% of those living with HIV were accessing antiretroviral therapy (WHO HIV ...

Review of current evidence indicates immune checkpoint inhibitors offer comparable efficacy and safety for NSCLC in people living with HIV, with no adverse impact on viral load or CD4 counts.

This transcript has been edited for clarity. Michael Saag, MD: Hello. I'm Dr Michael Saag, and welcome to Medscape InDiscussion: HIV. Today we're talking about antiretroviral therapy, maintenance, and ...